| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 8,389,486 | 6,061,408 | ||
| Marketable securities | 3,973,090 | 9,840,366 | ||
| Prepaid expenses and other current assets | 1,098,429 | 1,299,016 | ||
| Total current assets | 13,461,005 | 17,200,790 | ||
| Property and equipment, net | 35,977 | 39,524 | ||
| Operating lease right-of-use assets | 93,090 | 143,240 | ||
| Other assets | 36,738 | 36,738 | ||
| Total assets | 13,626,810 | 17,420,292 | ||
| Accounts payable and accrued expenses | 3,946,018 | 4,752,848 | ||
| Operating lease liabilities, current | 93,954 | 131,515 | ||
| Total current liabilities | 4,039,972 | 4,884,363 | ||
| Operating lease liabilities, net of current portion | - | 13,524 | ||
| Preferred stock (1,000,000 authorized at june 30, 2025 and december 31, 2024 .0001 par value) (zero shares issued and outstanding at june 30, 2025 and december 31, 2024) | - | 0 | ||
| Total liabilities | 4,039,972 | 4,897,887 | ||
| Common stock (25,000,000 authorized at september 30, 2025 and december 31, 2024 .0001 par value) (11,040,219 shares and 10,784,725 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively) | 1,104 | 1,078 | ||
| Additional paid-in capital | 98,616,239 | 97,366,699 | ||
| Accumulated other comprehensive income | 40,333 | 48,043 | ||
| Accumulated deficit | -89,070,838 | -84,893,415 | ||
| Total stockholders equity | 9,586,838 | 12,522,405 | ||
| Total liabilities and stockholders equity | 13,626,810 | 17,420,292 | ||
Lantern Pharma Inc. (LTRN)
Lantern Pharma Inc. (LTRN)